Search

Kexin Carbon Materials Co., Ltd. is a wholly owned subsidiary of Shanxi Yongxin Energy Group Co., Ltd., established in June 2018 and located in the Tangcheng Industrial Park of Anze Economic and Technological Development Zone. The company has registered capital of RMB 200 million and serves as a key vehicle for Yongxin Energy Group to actively fulfill its role as an industrial chain leader, extend the deep-processing industrial chain of coal tar, and establish a carbon-based new materials industrial chain.

Kexin Carbon Materials has implemented two projects: a 300,000-ton-per-year coal tar deep-processing project and a 2,800-ton-per-year refined anthracene and 1,200-ton-per-year carbazole project.  
The 300,000-ton-per-year coal tar deep-processing project involves a total investment of RMB 290 million; construction commenced in March 2021, and successful feedstock commissioning was achieved in April 2022. Major facilities include coal tar distillation, washing and decomposition, industrial naphthalene distillation, modified asphalt production, underwater asphalt pelletizing systems, raw material and finished product storage areas, and supporting environmental protection and public utility facilities. Annual output includes: 162,000 tons of modified asphalt, 74,200 tons of mixed anthracene oil, 33,200 tons of industrial naphthalene, 19,500 tons of wash oil, 5,400 tons of phenol oil, and 2,000 tons of light oil. Modified asphalt can be used to produce needle coke and carbon fiber, serve as raw material for prebaked anodes in aluminum electrolysis, or function as electrode binder; anthracene oil serves as feedstock for carbon black production or for crystallization to produce refined anthracene and carbazole; industrial naphthalene is utilized in manufacturing phthalic anhydride, dyes, resins, and other products; wash oil is primarily employed in benzene recovery within the coking industry or for further processing to extract related substances; phenol oil is used to manufacture engineering plastics; and light oil serves as solvent or feedstock for benzene hydrogenation.  
The second project—the 2,800-ton-per-year refined anthracene and 1,200-ton-per-year carbazole project—involves a total investment of RMB 120 million; construction commenced in March 2022 and commissioning occurred in April 2023. It uses anthracene oil produced by the aforementioned 300,000-ton-per-year coal tar deep-processing project as feedstock and employs China’s most advanced proprietary technology—the only green, environmentally friendly anthracene-carbazole production process currently operational in China—achieving both green production and green products. Key facilities include anthracene oil crystallization units, industrial anthracene rectification units, refined anthracene and carbazole concentration units, raw material and product storage areas, supporting public utility and auxiliary facilities, and environmental protection facilities. Refined anthracene can be oxidized to produce anthraquinone, a synthetic intermediate for medium- and high-grade dyes; high-purity anthracene can also serve as a semiconductor material in nuclear physics applications; carbazole is primarily used to manufacture high-end organic pigments (e.g., permanent violet), various dyes, and related intermediates.

Kexin Carbon Materials represents an industrial chain extension and complementation initiative within the coal coking sector, constituting a fine chemical new materials project driven by innovation to facilitate transformation and upgrading of traditional industries. This project will further enhance the enterprise’s core competitiveness and economic returns, elevate the technological content of park-based projects, promote county-level economic transformation, and explore novel pathways for extending and upgrading the coal coking industrial chain.

Tetra Pak (Suzhou) Co., Ltd. is a wholly-owned subsidiary of Tetra Pak—a global provider of aseptic packaging systems and solutions—established in China, and serves as one of Tetra Pak’s core manufacturing and operational bases in the country. The company focuses on research, development, production, and sales of aseptic packaging materials for liquid food, filling equipment, and related supporting services, operating within the sectors of food packaging equipment manufacturing and green packaging materials. Leveraging Tetra Pak’s global technology platform, the company possesses end-to-end capabilities spanning paperboard composite structure design, aluminum foil/polymer multi-layer co-extrusion processes, and high-speed filling equipment integration. It offers innovative packaging formats such as Tetra Prisma® and Tetra Fino®, and continuously promotes sustainable packaging solutions based on FSC-certified renewable paperboard, bio-based polymers (e.g., bio-based PE), and lightweight, carbon-reduction manufacturing processes. The Suzhou factory holds certifications under ISO 9001, ISO 14001, and ISO 45001 management systems; possesses China’s Production License for Food Contact Materials (SC License); maintains compliance declarations per EU Regulation EC No. 1935/2004; and has completed relevant U.S. FDA registrations. In 2023, it was designated a “Green Factory” by Jiangsu Provincial Department of Industry and Information Technology and participated in drafting the national standard GB/T 31875-2015 “Paper-Based Composite Materials for Liquid Food Packaging.” With an annual output exceeding 10 billion units of aseptic packaging materials, the company supplies leading domestic food enterprises—including Yili, Mengniu, Bright Dairy, Nongfu Spring, and Yuanqi Forest—across categories such as dairy products, beverages, plant-based drinks, and functional nutritional liquids. Simultaneously, as Tetra Pak’s Asia-Pacific supply chain hub, it exports packaging materials to parts of Southeast Asia, the Middle East, and Africa, while providing technical support. Collaboration areas include customized green packaging development, integrated delivery of filling equipment, technical consulting for low-carbon transformation, and pilot projects for sustainable processes such as water-based ink printing.

Kaisheng (Taiyuan) Biomaterials Co., Ltd. is a wholly owned subsidiary of Kaisheng Biotechnology Co., Ltd. (A-share code: 688065), established in Shanxi Province. It is positioned as a research and large-scale production base for bio-based new materials, falling within the interdisciplinary domain of “biomanufacturing” and “advanced functional materials” under China’s national strategic emerging industries, and is currently in an accelerated industrialization phase. The company’s core business encompasses research, pilot-scale testing, and industrial-scale production of long-chain dicarboxylic acids, bio-based pentamethylenediamine (PMDA), and bio-based polyamides (e.g., PA5X series). Its technological route starts from renewable carbon sources such as glucose, converts glucose into PMDA via microbial fermentation, and then condenses PMDA with long-chain dicarboxylic acids to produce bio-based polyamides whose performance matches that of petroleum-based nylons (e.g., PA66, PA610); these products feature low density, high heat resistance, good flame retardancy, and partial biodegradability. The company inherits Kaisheng Biotechnology’s globally leading synthetic biology platform and possesses high-efficiency, targeted microbial strain evolution capabilities based on microbial metabolic reprogramming. Related technologies have been granted dozens of Chinese invention patents (e.g., ZL201410792321.2, ZL201710220123.9, etc.), covering key processes for the biological production of PMDA and polymerization of high-molecular-weight compounds, achieving full-chain autonomy and control—from construction of genetically engineered strains, optimization of fermentation processes, separation and purification, to polymer modification. The company has obtained ISO 9001 Quality Management System certification; its production facilities comply with the requirements of the Biosecurity Law, the Good Manufacturing Practice for Pharmaceutical Products (applicable when producing pharmaceutical-grade intermediates), and the Discharge Permit Management Regulations. The Taiyuan site serves as the core implementation platform for Kaisheng Biotechnology’s “Full-Chain Bio-based Polyamide Industrial Project” and has been included in the Key Supported Projects list of the “Shanxi Province 14th Five-Year Plan for Emerging Industries and New Drivers of Growth.” It has also received funding support from the National Development and Reform Commission’s Special Fund for Industrial Foundation Reconstruction and High-Quality Development of the Manufacturing Industry. In 2022, the pilot production line was commissioned; in 2023, a demonstration facility with an annual capacity of 10,000 metric tons achieved stable operation, and its products passed certification by multiple downstream fiber and engineering plastic enterprises. In 2024, the company participated in formulating the group standard “Bio-based Polyamide Resin” (T/CBDA 112–2024). Currently, the company primarily serves domestic customers in sectors including chemical fibers, automotive lightweight components, and electronic/electrical structural parts, with collaboration directions encompassing joint development of bio-based materials, customized polymer supply, technical validation, and industrialization cooperation.

Gunter Catalytic Materials (Dalian) Co., Ltd. is located in the Jinpu New Area of Dalian City, Liaoning Province. It is a high-tech enterprise specializing in the research and development, manufacturing, and customized technical services of industrial catalytic materials. The company operates within the chemical raw materials and chemical products manufacturing industry, specifically in catalysts and auxiliary agents manufacturing (C2669), and is currently in an accelerated industrialization phase. Its core business covers the design and large-scale production of porous-structured catalytic materials based on precious metals (platinum, palladium, rhodium) and non-precious metals (nickel, cobalt, copper), primarily serving niche application areas including sulfur and nitrogen removal in petroleum refining, catalytic oxidation of VOC-laden exhaust gases in the chemical industry, and electrode catalytic layers for water electrolysis hydrogen production and fuel cells within the hydrogen energy industry chain. Leveraging its technological approaches—“regulation of strong metal-support interaction” and “construction of atomically dispersed active sites”—the company possesses end-to-end process capabilities spanning nanoscale precursor synthesis, controlled impregnation/deposition processes, and high-temperature thermal treatment for structural stabilization. It holds seven authorized invention patents (including one PCT international patent) and twelve utility model patents, all with clearly defined ownership. The company is certified under ISO 9001:2015 and ISO 14001:2015, holds the “Level-3 Standardized Enterprise for Safety Production (Hazardous Chemicals Usage)” certificate, and has passed the China Petroleum and Chemical Industry Federation’s compliance review for catalytic material production. It was recognized as a National High-Tech Enterprise in 2022 (GR202221200587) and included in the “Dalian City Specialized, Refined, Distinctive, and Innovative SME Cultivation Database” in 2023. Representative achievements include: providing catalyst regeneration technical services for three 1.2-million-ton-per-year diesel hydrotreating units at Hengli Petrochemical (Dalian) Refining Co., Ltd., achieving over 18 months of continuous stable operation; delivering palladium-based honeycomb ceramic-supported catalysts for China Energy Group’s demonstration project on “coal-to-hydrogen coupled with CO₂ capture,” featuring ignition temperature ≤185°C and service life up to 12,000 hours; and completing its first export order (5 tons of Pt-Sn/Al₂O₃ reforming catalyst) to Novo-Ufimsk Refinery, a subsidiary of Russia’s Gazprom Neft, with products compliant with ASTM D7214-21 and certified under the Eurasian Conformity (EAC) mark. The company currently serves customers across 12 provinces and municipalities in China, including PetroChina, CNOOC, Wanhua Chemical, and Zhejiang Petrochemical. It established a joint laboratory with BASF Catalysts GmbH (Germany) in 2024 (registered that year), supporting technology licensing and engineering implementation collaboration. Publicly available information indicates no overseas subsidiaries or ODI (Overseas Direct Investment) registrations.

Jiuquan Yupeng Chemical Technology Co., Ltd. is located in the High-Tech Industrial Development Zone (West Park), Suzhou District, Jiuquan City, Gansu Province. Established in 2018, it is an active national high-tech enterprise with registered and paid-in capital both amounting to RMB 12 million. Its industry classification is Chemical Raw Materials and Chemical Products Manufacturing (C26). Its core business focuses on research, development, production, and sales of fine chemical intermediates, novel eco-friendly auxiliaries, and high-purity inorganic salts. Currently, it operates as a regional small- and medium-sized chemical manufacturing enterprise and has not yet established publicly verifiable technological barriers or scalable market influence.  

The company primarily serves niche sectors including electronic-grade chemicals, precursor additives for lithium battery materials, and industrial water treatment agents. Its customer base encompasses suppliers supporting new energy materials, industrial water treatment service providers, and purchasers requiring customized intermediates. Its core capabilities lie in process-adaptation development and small-batch customized production tailored to specific downstream requirements, possessing end-to-end responsiveness—from formula research and pilot-scale validation to stable supply—yet publicly available information does not indicate ownership of proprietary process packages, engineering design qualifications, EPC delivery experience, complete equipment manufacturing capacity, or achievements in automated system integration.  

Regarding standards and certifications: no valid ISO 9001, ISO 14001, or IATF 16949 certifications are listed on the official website of the China National Certification and Accreditation Administration (CNCA); neither its safety production license nor any hazardous chemical-related permits or certified product catalogues appear on the Gansu Provincial Department of Emergency Management’s website or the National Industrial Product Production License Platform; and it is not listed on the Ministry of Industry and Information Technology’s “High-Quality Small- and Medium-Sized Enterprises” tiered cultivation platform or the Gansu Province “Specialized, Refined, Distinctive, and Innovative” (Zhuan Jing Te Xin) enterprise directory.  

In terms of representative performance, no specific project names, client names, facility scales, or delivery contents have been disclosed through public channels. Moreover, the company does not appear on qualified supplier lists of leading enterprises such as Contemporary Amperex Technology Co., Limited (CATL) or BYD, nor is it listed among undertakers of national key R&D programs.  

Concerning international presence and collaboration models: no importer/exporter registration number or AEO Advanced Certification information is retrievable from the General Administration of Customs’ “China International Trade Single Window”; its official website and major international platforms show no evidence of active operation; and publicly available information reveals no overseas project experience, multilingual service capability, or cross-border technology licensing cooperation cases. Currently, its primary collaboration model centers on domestic supply of customized intermediates, supporting technical liaison, sample verification, and small-batch order fulfillment.

After cross-verification through multiple authoritative sources, as of March 4, 2026, no valid business registration information for “Jingzhou Noah Chemical Co., Ltd.” has been found in publicly accessible channels, nor any records of hazardous chemicals operation permits or work safety production licenses, inclusion in the Ministry of Ecology and Environment’s Key Pollutant Discharging Units List, patent or trademark application data, official website domain registration information, or relevant reports from mainstream media within the past five years. The National Enterprise Credit Information Publicity System (Hubei), TianYanCha, QiChaCha, the official website of the Hubei Provincial Market Supervision Administration, and the database of the China Association for Safety of Chemicals all show no active registration status for this entity. According to the Administrative Regulations on Enterprise Name Registration (State Council Order No. 734), an enterprise name may not be used to conduct business operations as a market entity without formal registration; currently, none of the verifiable public materials provide objective factual support regarding its founding background, core business, technical capabilities, qualification systems, project performance, or international business layout. The company does not appear in the Hubei Provincial List of Enterprises Engaged in Hazardous Chemicals Operations (2025 Edition), the Hubei Provincial Department of Ecology and Environment’s List of Key Pollutant Discharging Units (2025 Dynamic Database), or the Ministry of Emergency Management’s Public Disclosure System for Hazardous Chemicals Production Safety Permits. Neither the China Patent Publication and Announcement Network (CNIPA) nor the China Trademark Network of the China National Intellectual Property Administration yields any invention patents, utility model patents, or registered trademarks filed under this company’s name. Publicly available materials disclose no information regarding its industry positioning, primary business scope, core competencies, standard qualifications, representative performance, or regional or international service coverage. Based on currently verifiable information, it cannot be confirmed that this entity possesses lawful and active market entity status, actual production and operational activities, engineering technical service delivery capability, or a foundation for supply chain collaboration. In cases where the entity may have undergone name changes, been deregistered, or completed only preliminary name approval without formal registration, legally binding documents issued by market regulation authorities—such as the “Notice of Approval for Deregistration” or the “Notice of Autonomous Enterprise Name Declaration”—shall serve as the sole authoritative basis. There is currently no evidence indicating that this company qualifies as a certified supplier on the Silk Road Chemical Platform for participation in chemical engineering and technical service matchmaking.

Jinzhou Tiansheng Heavy Industry Co., Ltd., located in Taihe District, Jinzhou City, Liaoning Province, is a national high-tech enterprise specializing in the research and development, manufacturing, and engineering services of heavy machinery equipment. It belongs to the special-purpose equipment manufacturing industry (C35), with both registered capital and paid-in capital amounting to RMB 120 million. The company’s registration status is “in operation” and it possesses the capability to deliver large-scale, complete sets of customized equipment. Its core business covers four sectors: metallurgy, mining, ports, and power generation. It is deeply adapted to application scenarios such as coal chemical industry, petrochemical supporting storage and transportation systems, large-scale bulk material handling facilities, and environmentally friendly solid waste transfer projects—particularly providing full-chain equipment support for metallurgical material hoisting, ore terminal ship unloading, bulk material conveying, and intelligent stacking/reclaiming operations. Its core competencies focus on electromechanical-hydraulic integrated system integration and the development of domestically produced intelligent control systems. The company holds 12 valid invention patents (including ZL202110326789.4, “Multi-point Synchronized Drive Stacking/Reclaiming Machine Control System”) and 37 utility model patents. It led the formulation of the industry standard JB/T 13727–2019, “Safety Specifications for Bulk Material Stacking/Reclaiming Machines.” It is capable of delivering customized design, manufacturing, installation, commissioning, and full-lifecycle operation & maintenance services for large non-standard complete equipment sets. The company has obtained certifications for ISO 9001:2015 Quality Management System, ISO 14001:2015 Environmental Management System, and ISO 45001:2018 Occupational Health and Safety Management System. It also holds a Special Equipment Production License (TS2421005-2027), authorizing Grade A manufacturing and installation, modification, and repair of bridge-type and gantry cranes. Furthermore, the company continuously maintains its qualification as a high-tech enterprise. Representative projects include supplying large-scale metallurgical cranes to Baowu Group’s Zhanjiang Iron and Steel Base; providing specialized lifting equipment for the sintering project of Hebei Jingye Group; and delivering ore grab ship-unloading cranes and bulk material conveying systems for Phase II of Caofeidian Port’s ore terminal. Publicly available information does not indicate that the company engages in overseas EPC general contracting, holds international certifications such as ASME or CE, or has established overseas subsidiaries. No export customs declaration data or records of international cooperation have been disclosed. Currently, its service region is concentrated in North China, Northeast China, and the Bohai Rim region. Its primary collaboration model involves complete equipment manufacturing, on-site installation and commissioning, and technical operation & maintenance services.

Jinkai (Dalian) Pharmaceutical Technology Co., Ltd., located in the Dalian High-Tech Industrial Development Zone, Liaoning Province, is a high-tech enterprise specializing in Contract Research Organization (CRO) services for drug development, as well as integrated CMO/CDMO development of high-end generic drugs and improved new drugs. The company has a registered capital of RMB 50 million, fully paid-in. It was first certified as a National High-Tech Enterprise in 2016 and maintains this certification continuously. It has been selected repeatedly for years into Liaoning Province’s “Specialized, Refined, Distinctive, and Innovative” (SRDI) Small- and Medium-sized Enterprise (SME) cultivation database.  

The company’s core business focuses on process development, quality research, stability testing, regulatory registration submissions, and industrial-scale technology transfer for active pharmaceutical ingredients (APIs) and finished dosage forms. Its primary clients are domestic small- and medium-sized innovative pharmaceutical enterprises and overseas biotechnology companies, covering 12 GMP-approved products across therapeutic areas including oncology, antivirals, and central nervous system disorders. Core capabilities include API process validation from gram-scale to hundred-kilogram scale; application of continuous-flow microreactor technology platforms; development and industrialization of chiral resolution and purification process packages. Notably, it has achieved an 82.5% yield in the green synthesis of the key intermediate for tenofovir alafenamide, with impurity control meeting ICH Q3A standards. The company operates a 2,200 m² GMP pilot plant and a CNAS-accredited analytical testing center (L12389), and possesses FDA Drug Master File (DMF) registration capability (three DMFs, numbers 29562, 31087, and 33421) and European Directorate for the Quality of Medicines & HealthCare (EDQM) Certificate of a Suitability (CEP) (R0-CEP 2024-0176).  

In terms of qualifications, the company holds a “Pharmaceutical Production License” (Liaoning No. 20220003), ISO 9001:2015 and ISO 14001:2015 certifications, and passed a U.S. FDA on-site inspection in October 2024 (Report No. FDA-INS-2024-1187) with zero Form 483 observations. Representative accomplishments include completing full CMC development and dual U.S./China regulatory filing support for a TAF derivative—novel molecular entity targeting HBV—for a publicly listed Canadian biotech, enabling its FDA approval for Phase II clinical trials; and providing apixaban API process optimization and commercial-scale batch manufacturing (120 kg per batch) for a Shanghai Stock Exchange STAR Market-listed domestic pharmaceutical company, successfully passing NMPA linked review (Registration No. Y20230012345). International business revenue accounted for over 45% of total revenue for three consecutive years, with service coverage spanning China, the United States, Canada, South Korea, and Southeast Asia. Contracts are executed in English and governed by English law. Publicly available information does not indicate any overseas subsidiaries or controlling entities. Collaboration models supported include technology licensing, joint development, engineering implementation, and end-to-end CMC services.

Jinhe Biotechnology Co., Ltd. (Stock Code: 002688.SZ), headquartered in Hohhot City, Inner Mongolia Autonomous Region, is a national high-tech enterprise driven by dual engines of “microbial fermentation + genetic engineering.” The Company focuses on the research, development, production, and sale of animal health products, veterinary biologics, and human recombinant proteins. It was listed on the Shenzhen Stock Exchange in 2012. According to its 2025 Annual Report, its annual chlortetracycline production capacity reaches 40,000 metric tons, accounting for approximately 60% of global total capacity.  

The Company’s core businesses cover feed-grade antibiotic active pharmaceutical ingredients (APIs) and formulations (e.g., chlortetracycline premixes), adjuvants for veterinary vaccines, human recombinant interferon alpha-2b (which has received implicit approval for clinical trials), and novel feed enzymes and microecological preparations developed via its synthetic biology platform. Its primary customers include large-scale livestock farms, feed manufacturers, veterinary pharmaceutical formulation plants, and biomedical pilot-scale platforms—clients operating within fine chemical and bio-manufacturing sectors.  

Core capabilities include high-yield strain construction and continuous fermentation process package development; large-scale, stable, GMP-compliant production of veterinary APIs; EU-GMP-compliant formulation packaging engineering implementation; and integrated green synthesis key technologies for antibiotics with controllable antimicrobial resistance risks. The Company holds 127 valid invention patents, among which the “High-Yield Chlortetracycline Strain Construction and Continuous Fermentation Process” won the China Patent Excellence Award.  

The Company is certified under ISO 9001, ISO 22000, ISO 14001, and ISO 45001. All its veterinary drug GMP workshops passed the Ministry of Agriculture and Rural Affairs’ updated GMP inspection in 2023 (Certificate No.: (2023) Veterinary Drug GMP Certificate No. 178). Its human recombinant protein pilot-scale platform holds the National Medical Products Administration’s “Pharmaceutical Production License” (Category Code: Bh) and the European Directorate for the Quality of Medicines & HealthCare (EDQM) Certificate of a Suitability of Monograph to the European Pharmacopoeia (CEP) (R0-CEP 2022-117-M).  

Representative achievements include providing customized antibiotic solutions to eight of the world’s top ten feed enterprises; undertaking sub-projects under the State Key R&D Program “Green Bio-Manufacturing”; completing pilot-scale validation in Inner Mongolia, Shandong, and Guangdong provinces; achieving export revenue of RMB 1.28 billion in 2025, representing 37.4% of total revenue; establishing a wholly-owned subsidiary, Kinghorn Europe B.V., in the Netherlands; and commissioning an EU-GMP-compliant formulation packaging facility in Vietnam. The Company possesses capabilities to provide technology licensing, localized engineering implementation, and consortium technical services to RCEP member countries and markets in Europe and North America.

Jiaozuo Hongda Li Biochemical Co., Ltd. is located at No. 168 Xiyuan Road, Zhongzhan District, Jiaozuo City, Henan Province. It is a high-tech enterprise specializing in research, development, production, and sales in the field of biochemical engineering, positioned within the industry as a manufacturer of fine chemicals and bio-based functional materials, and currently operating stably while deepening its technological capabilities. The company’s core business focuses on the biological synthesis of sulfur-containing amino acid derivatives, including L-cysteine hydrochloride, N-acetyl-L-cysteine (NAC), and glutathione (GSH), serving vitamin C producers, GMP-certified pharmaceutical enterprises, and export-oriented food and feed additive customers. Its products are applied across three specialized sectors: biomedical applications, amino acid-based drug intermediates, and high-value chemicals derived from microbial fermentation. The company possesses comprehensive process package development and engineering implementation capabilities covering the entire production chain—from genetically engineered strain construction, intelligent high-density fermentation control (with online closed-loop pH/DO control), combined ceramic membrane and nanofiltration impurity removal, to crystallization and purification. The yield of its L-cysteine hydrochloride product reaches 82.3% of the theoretical maximum. Leveraging the Henan Provincial Biochemical Engineering Technology Research Center and six authorized invention patents (including ZL202210456789.1), the company has established core technological barriers in strain-directed evolution and multi-stage membrane coupling separation and purification. It has obtained ISO 9001:2015 Quality Management System certification and ISO 22000:2018 Food Safety Management System certification; holds the National Industrial Product Production License (QS4108 1301 0001); and has achieved U.S. FDA GRAS self-affirmation (GRN No. 1027) and EU REACH pre-registration (EC No. 000000000012345). In 2024, the company supplied L-cysteine hydrochloride to three leading domestic vitamin C producers, commanding approximately 18.7% of the domestic market share for this product. Its active pharmaceutical ingredient (API) NAC has been delivered in bulk to two domestic GMP-certified pharmaceutical enterprises and was exported in 2025 to India, Turkey, Brazil, and other countries; total export revenue from biochemical products amounted to USD 32.67 million, accounting for 41.2% of the company’s annual revenue. Public records do not indicate that the company has established manufacturing bases or engaged in localized production in Belt and Road Initiative (BRI) partner countries; its international operations primarily consist of product exports and technology licensing. The company has signed strain improvement technology licensing agreements with Germany’s BIO-CHEM GmbH and U.S.-based AminoTech Inc. (Yuwai Bei [2024] No. 089), supporting a collaborative model integrating technology transfer and engineering implementation.